BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2005

View Archived Issues

Activation of mGlu4 receptors - a pharmacological strategy against medulloblastoma

Read More

Hypoglycemic effects of FR-225654 in preclinical models of diabetes

Read More

Pimecrolimus reported effective in facial seborrheic dermatitis

Read More

Amarillo updates low dose oral interferon progress

Read More

A novel bimosiamose formulation reduces plaque thickness in psoriasis

Read More

NeoPharm establishes bioequivalence for LEP-ETU

Read More

LigoCyte receives NIH grant for intranasal anthrax vaccine

Read More

Positive results of phase III trial of oxymorphone ER

Read More

Genaissance enters into HAP technology license agreement with Sankyo

Read More

Phase II program cleared for cholesterol-lowering drug FM-VP4

Read More

Acadia receives milestone under Allergan collaboration

Read More

Allergan and GSK enter product agreements

Read More

Japanese National Institute of Infectious Diseases to study Ampligen

Read More

AVR-118 begins phase I study in type 2 diabetes patients

Read More

Barbeau Pharma progresses pipeline

Read More

EGF/gastrin combination, E1-INT, reverses hyperglycemia and increases beta-cell mass

Read More

CTB-Insulin oral vaccine produced in silkworm larvae protects NOD mice from autoimmune diabetes

Read More

Anti-IL-13 antibody (CAT-354) effective against allergic airway and esophageal inflammation in mice

Read More

Data on novel SERM LY-2066948.HCl

Read More

Stockholders of Salix and InKine approve merger

Read More

Five reports of Guillain-Barre syndrome following administration of Menactra

Read More

Oracea NDA submission accepted for review

Read More

Discontinuation of phase III Canvaxin study in stage III melanoma

Read More

European approval for Vasovist for magnetic resonance angiography

Read More

Update on the antiepileptic effects of adjunctive rufinamide

Read More

Antipsychotics demonstrate similar efficacy in schizophrenia patients

Read More

Intralesional bleomycin plus electroporation under evaluation for metastatic melanoma

Read More

Recent patents disclose novel analgesic agents

Read More

New antiinfective agents described in recent patents

Read More

New anticoagulants prepared and tested by Aventis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing